Impact News +++ XFRA: RER1: Wiederaufnahme/Resumption (XETRA) +++ RECORDATI Aktie -3,02%

PULMATRIX Aktie

>PULMATRIX Aktienkurs

1.408 EUR -24.0% (TradegateBSX)

Ask: 1.364 EUR / 1500 Stück

Bid: 1.288 EUR / 4700 Stück

Tagesumsatz: 10615 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

PULMATRIX Aktie über LYNX handeln

Intraday

1 Jahr

>PULMATRIX Performance

1 Woche: -0,9%

1 Monat: -31,2%

3 Monate: -7,3%

6 Monate: -50,6%

1 Jahr: -71,2%

laufendes Jahr: -2,0%

>PULMATRIX Aktie

Name:

PULMATRIX INC. DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US74584P3010 / A3DWEE

Symbol/ Ticker:

2PU (Frankfurt) / PULM (NASDAQ)

Kürzel:

FRA:2PU, ETR:2PU, 2PU:GR, NASDAQ:PULM

Index:

Webseite:

https://www.pulmatrix.com..

Profil:

Pulmatrix Inc. is a biotechnology company focused on the discovery and development of innovative inhaled therapies to address significant unmet needs in respiratory diseases. The company's primary fun..
>Volltext..

Marktkapitalisierung:

7.11 Mio. EUR

Unternehmenswert:

3.63 Mio. EUR

Umsatz:

EBITDA:

-4.45 Mio. EUR

Nettogewinn:

-4.45 Mio. EUR

Gewinn je Aktie:

-1.22 EUR

Schulden:

Liquide Mittel:

3.52 Mio. EUR

Operativer Cashflow:

-4.68 Mio. EUR

Bargeldquote:

12.43

Umsatzwachstum:

-100%

Gewinnwachstum:

52.4%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

PULMATRIX

Letzte Datenerhebung:

26.03.26

>PULMATRIX Kennzahlen

Aktien/ Unternehmen:

Aktien: 3.65 Mio. St.

Frei handelbar: 100%

Leerverk. Aktien: 0.12%

Rückkaufquote: -

Mitarbeiter: 2

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 2.29

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -73.31%

Eigenkaprendite: -80.93%

>PULMATRIX Peer Group

Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika

>PULMATRIX Chart & Kurs - NASDAQ

>PULMATRIX News

26.03.26 - 14:03	XFRA: 2PU: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN PULMATRIX INC. DL-,0001 2PU US74584P3010 AB/FROM ONWARDS 26.03.2026 13:54 CET...

26.03.26 - 13:31	XFRA: 2PU: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL PULMATRIX INC. DL-,0001 2PU US74584P3010 BAW/UFN...

26.03.26 - 13:31	XFRA: INSTRUMENT_SUSPENSION - US74584P3010 (XETRA)
	Instrument ID [10374295] (2PU - US74584P3010) suspended...

02.03.26 - 14:06	Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities (PR Newswire)
	Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agreement - Pulmatrix advances existing discussions on alternative merger opportunities -......

26.02.26 - 16:15	Pulmatrix GAAP EPS of -$1.41 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 14:09	Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results (PR Newswire)
	Plans to License or Monetize our Migraine and Inhalation Assets Continue FRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products......

18.12.25 - 14:09	Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives (PR Newswire)
	Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission FRAMINGHAM, Mass., Dec. 18, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the......

16.10.25 - 14:18	Pulmatrix GAAP EPS of -$0.24 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

16.10.25 - 14:09	Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets (PR Newswire)
	As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule drugs to the lungs by inhalation to treat migraine and respiratory diseases FRAMINGHAM,......

07.08.25 - 04:24	Pulmatrix (PULM) Q2 Revenue Falls 100% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.25 - 14:07	Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets (PR Newswire)
	Proposed merger anticipated to close in 2025 As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small or large molecule drugs to the lungs by inhalation FRAMINGHAM,......

15.05.25 - 14:30	Pulmatrix GAAP EPS of -$0.50 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.05.25 - 14:06	Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets (PR Newswire)
	Registration statement for proposed Cullgen merger declared effective by the SEC Proposed merger anticipated to close in June As part of proposed merger, Pulmatrix currently intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development......

21.03.25 - 13:18	Pulmatrix GAAP EPS of -$2.62, revenue of $7.81M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

21.03.25 - 13:07	Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets (PR Newswire)
	Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: So wertlos ist keiner, daß er nicht wenigstens als schlechtes Beispiel herhalten könnte. - Markus M. Ronner

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram